Cidara Therapeutics, Inc. (CDTX)
Cidara Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative antifungal and antiviral medicines. The company's portfolio includes therapies aimed at addressing serious infectious diseases, with an emphasis on immunocompromised and immunosuppressed patient populations. Cidara leverages novel delivery platforms and targeted approaches to improve treatment outcomes in difficult-to-treat infections.
Company News
Cidara Therapeutics announced a presentation at the ESWI 2025 conference, highlighting translational efficacy data for CD388, its long-acting antiviral drug for influenza prevention. JP Morgan initiated coverage with an Overweight rating and $200 price target, boosting market sentiment.
Cidara Therapeutics received FDA Breakthrough Therapy designation for its investigational non-vaccine flu drug CD388, which aims to prevent seasonal flu for patients unable or unwilling to take traditional vaccines. The announcement boosted the company's stock price by over 12%.
Cidara Therapeutics granted non-qualified stock options and restricted stock units totaling 12,100 shares to two new employees under its 2020 Inducement Incentive Plan, with stock options priced at $48.71 per share and vesting over four years.
Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.66% and 26.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Penny stocks to watch before next week. The post 7 Top Penny Stocks Under $5; Time To Buy Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.